Brands are showing up, consumers expect them to
Danette Breitenbach
Build for the long-term, responsibly
Danette Breitenbach
Trending
Subscribe & Follow
Advertise your job vacancies
Jobs
- IT Learner Centurion
- Group IT Network Engineer Centurion
- C# Software Developer Waterfall
- HR Business Partner Randburg
- Marketing Manager Nelsp
- Intermediate C# Software Developer Waterfall
- Executive Director to the CEO Bloemfontein
- Motor Insurance Claims Consultant George
- Creative designer at MasterPiece Puzzles Cape Town
- Brand Activations Coordinator National
Nestlé to acquire biopharmaceutical company Aimmune
Nestlé Health Science (NHSc) is to acquire Aimmune Therapeutics in accordance with a definitive agreement between Nestlé and the biopharmaceutical company.
NHSc currently has a total investment in Aimmune of $473m, an approximate 25.6% equity ownership stake. The company made its initial investment of $145m in Aimmune in November 2016, followed by further investments of $30m in February 2018, $98m in November 2018 and $200m in January 2020.
